This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, NLTX, CYBN, BIOA, and VIRIShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Cerecor vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Cerecor (NASDAQ:CERC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings. Does the media favor CERC or MOR? In the previous week, MorphoSys' average media sentiment score of 1.08 beat Cerecor's score of 0.16 indicating that MorphoSys is being referred to more favorably in the news media. Company Overall Sentiment Cerecor Neutral MorphoSys Positive Which has preferable valuation and earnings, CERC or MOR? Cerecor has higher earnings, but lower revenue than MorphoSys. Cerecor is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerecor$6.70M129.25-$63.50M-$0.57-15.82MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Is CERC or MOR more profitable? MorphoSys has a net margin of -226.79% compared to Cerecor's net margin of -1,194.82%. Cerecor's return on equity of -261.82% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Cerecor-1,194.82% -261.82% -133.96% MorphoSys -226.79%-694.31%-22.55% Which has more volatility and risk, CERC or MOR? Cerecor has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Do institutionals & insiders believe in CERC or MOR? 62.8% of Cerecor shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCerecor beats MorphoSys on 7 of the 12 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$866.00M$778.29M$5.75B$9.81BDividend YieldN/A4.84%3.91%4.13%P/E Ratio-15.821.1831.1125.08Price / Sales129.2525.64435.45100.03Price / CashN/A19.5636.7858.67Price / Book41.006.599.086.18Net Income-$63.50M-$4.67M$3.26B$265.11M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$9.02+0.8%N/A-3.0%$866.00M$6.70M-15.8231Gap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$58.59+1.0%N/A+23.9%$2.54BN/A-58.5930CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.4842 of 5 stars$13.02+4.7%$21.43+64.6%+37.0%$907.27M$122.87M-8.68460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A+9.0%$590.63MN/A-6.7783High Trading VolumeMBXMBX Biosciences2.562 of 5 stars$12.53+11.3%$37.63+200.3%N/A$418.80MN/A-2.7636News CoverageNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-42.4%$191.25MN/A-6.5490News CoverageHigh Trading VolumeCYBNCybin2.4409 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450News CoveragePositive NewsBIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/ANews CoverageVIRIVirios TherapeuticsN/A$4.77-2.5%$5.00+4.8%+2,508.5%$91.86MN/A-17.675Gap Down Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives BioAge Labs Alternatives Virios Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access